AAPL 221.4826 -1.0134% MSFT 389.31 -1.4804% NVDA 113.075 -6.3096% GOOGL 165.94 -2.7087% GOOG 167.985 -2.7808% AMZN 200.22 -2.6688% META 607.7499 -2.9634% AVGO 178.56 -5.1524% LLY 830.925 -2.5136% TSLA 270.5178 -6.1158% TSM 171.84 -5.0083% V 343.245 -0.399% JPM 250.25 -0.3504% UNH 514.545 0.2172% NVO 71.78 -2.4728% WMT 84.62 -0.1652% LVMUY 126.55 -2.0132% XOM 118.105 1.2994% LVMHF 635.0 -2.0757% MA 546.11 0.1743%
AAPL 221.4826 -1.0134% MSFT 389.31 -1.4804% NVDA 113.075 -6.3096% GOOGL 165.94 -2.7087% GOOG 167.985 -2.7808% AMZN 200.22 -2.6688% META 607.7499 -2.9634% AVGO 178.56 -5.1524% LLY 830.925 -2.5136% TSLA 270.5178 -6.1158% TSM 171.84 -5.0083% V 343.245 -0.399% JPM 250.25 -0.3504% UNH 514.545 0.2172% NVO 71.78 -2.4728% WMT 84.62 -0.1652% LVMUY 126.55 -2.0132% XOM 118.105 1.2994% LVMHF 635.0 -2.0757% MA 546.11 0.1743%

Nov 26, 2024

DXCM:NASDAQ
Investment Type
Large-cap
Risk Level
Action
Rec. Price (US$)

Section 1: Company Overview and Fundamentals

1.1 Company Overview:

DexCom, Inc. (NASDAQ: DXCM) is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world.

Kalkine’s American Tech Report covers the Company Overview, Key positives & negatives, Investment summary, Key investment metrics, Top 10 shareholding, Business updates and insights into company recent financial results, Key Risks & Outlook, Price performance and technical summary, Target Price, and Recommendation on the stock.

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Copyright © 2024 Krish Capital Pty Ltd. All rights reserved.